NCT07271030 The Use of Cannabidiol Suppositories for Sexual Pain
| NCT ID | NCT07271030 |
| Status | Recruiting |
| Phase | — |
| Sponsor | London Metropolitan University |
| Condition | Well-Being, Psychological |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-01-16 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2026-01-16 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Research aim: To determine how cannabidiol suppositories might reduce sexual pain during intimacy. Outcomes are also hoped to increase sexual functioning, well-being, and quality of life. Research intention: If cannabidiol suppository intervention reduces sexual pain and increases general well-being, then this research would be repeated on a larger scale, targeting psychosexual services. A brief overview of the intervention: Quantitatively, randomisation of cannabidiol suppositories will be into dose-specific groups. The intervention will be delivered over a period of one month, with follow-up scheduled at 12 weeks. Qualitatively, participants were asked approximately eight open-ended feedback questions throughout the study.
Eligibility Criteria
Inclusion Criteria: * Has previously used cannabidiol in any capacity and has not experienced any allergic reaction * Is experiencing sexual pain * There will be an absence of co occurring difficulties * Has attempted sexual intercourse in the last month * Age 18 years or older * Read and write English * Patient Health Questionnaire 9 screening score range between 0-9 mild * General Anxiety Disorder 7 screening score range between 0-9 mild * There are no restrictions on sex, gender, sexuality, or disability Exclusion Criteria: Has experienced an allergic reaction to cannabidiol in any capacity * Has not attempted sexual intercourse in the last month * Has co occurring difficulties * Aged below 18 years old * Are not experiencing sexual pain * Patient Health Questionnaire 9 screening score range between moderate to severe - 10-27 * General Anxiety Disorder 7 screening score range between 10- 21.
Contact & Investigator
Samantha Banbury
PRINCIPAL INVESTIGATOR
London Metropolitan University
Frequently Asked Questions
Who can join the NCT07271030 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Well-Being, Psychological. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07271030 currently recruiting?
Yes, NCT07271030 is actively recruiting participants. Contact the research team at rpo@londonmet.ac.uk for enrollment information.
Where is the NCT07271030 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT07271030 clinical trial?
NCT07271030 is sponsored by London Metropolitan University. The principal investigator is Samantha Banbury at London Metropolitan University. The trial plans to enroll 50 participants.